Aminotriazolopyridines as kinase inhibitors

US12157733B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Junqing Guo · Princeton, US
• Amy C. Hart · Ewing, US
• John E. Macor · Guilford, US
• Michael E. Mertzman · New Hope, US
• William J. Pitts · Newtown, US
• Steven H. Spergel · Warrington, US
• Scott Hunter Watterson · Pennington, US
• Murugaiah Andappan Murugaiah Subbaiah · Komangalam, IN
• Jie Chen · Houston, US
• Carolyn Diane Dzierba · Middletown, US
• Guanglin Luo · Newtown, US
• Jianliang Shi · Furlong, US
• Sing-Yuen Sit · Meriden, US

Key dates

• Filing date: Dec 9, 2020
• Grant date: Dec 3, 2024
• Expiry date: Jul 14, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F9/6561
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds having formula (I)-(IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.